The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer

被引：155
|
作者：
Jordheim, Lars Petter [1 ,2 ]
Seve, Pascal [2 ,3 ]
Tredan, Olivier [5 ]
Dumontet, Charles [2 ,4 ]
机构：
[1] Univ Lyon 1, Fac Med Rockefeller, Lab Cytol Analyt, INSERM,U590, F-69008 Lyon, France
[2] Lyon Univ, Lyon, France
[3] Hosp Civils Lyon, Dept Internal Med, Lyon, France
[4] Hosp Civils Lyon, Hematol Lab, Lyon, France
[5] Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France
来源：
LANCET ONCOLOGY | 2011年 / 12卷 / 07期
关键词：
CELL LUNG-CANCER; MESSENGER-RNA EXPRESSION; HUMAN PANCREATIC-CANCER; GEMCITABINE-BASED CHEMOTHERAPY; CHROMOSOME SEGMENT 11P15.5; ANTITUMOR-ACTIVITY; MOLECULAR MARKERS; SINGLE NUCLEOTIDE; ERCC1; EXPRESSION; RANDOMIZED-TRIAL;
D O I：
10.1016/S1470-2045(10)70244-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The large subunit of human ribonucleotide reductase, RRM1, is involved in the regulation of cell proliferation, cell migration, tumour and metastasis development, and the synthesis of deoxyribonucleotides for DNA synthesis. It is also a cellular target for the chemotherapeutic agent, gemcitabine. RRM1 has been studied in a large number of patients with different types of cancer, such as non-small-cell lung cancer, pancreatic cancer, breast cancer, and biliary tract cancer, to establish its prognostic or predictive value when patients were treated with gemcitabine, and mRNA expression and genetic variants as determined by genotyping have in some cases been associated with clinical outcome of patients with cancer. Here, we review preclinical and clinical studies of RRM1 assessment and discuss the further steps in the development of this clinically pertinent biomarker.
引用
收藏
页码：693 / 702
页数：10
相关论文
共 50 条
  • [31] Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro
    Morikawa, Teppei
    Hino, Rumi
    Uozaki, Hiroshi
    Maeda, Daichi
    Ushiku, Tetsuo
    Shinozaki, Aya
    Sakatani, Takashi
    Fukayama, Masashi
    HUMAN PATHOLOGY, 2010, 41 (12) : 1742 - 1748
  • [32] Comparison of the expression of human equilibrative nucleotide transporter 1 (hENT1) and ribonucleotide reductase subunit M1 (RRM1) genes in seven non-Hodgkin lymphoma cell lines
    Zhao, H. B.
    Zhang, X. F.
    Shi, F.
    Zhang, M. Z.
    Xue, W. L.
    GENETICS AND MOLECULAR RESEARCH, 2016, 15 (02):
  • [33] Targeting ribonucleotide reductase subunit 2 (RRM2) to radio-sensitize glioblastoma
    Corrales-Guerrero, Sergio
    Cui, Tiantian
    Castro-Aceituno, Veronica
    Yang, Linlin
    Feng, Haihua
    Nair, Sindhu
    Shen, Changxian
    Venere, Monica
    Williams, Terence M.
    CANCER RESEARCH, 2023, 83 (07)
  • [34] Predictive utility of RRM1 promoter polymorphisms on outcome of patients with non-small cell lung cancer.
    Haura, EB
    Zheng, Z
    Gautam, A
    Sharma, S
    Cantor, A
    Sharma, A
    Bepler, G
    Lee, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 654S - 654S
  • [35] ERCC1 and RRM1 genes in lung cancer
    Carvalho, Lina
    Silva, Antonio
    Andrade, Claudia
    Barroso, Claudia
    Farinha, Claudia
    Fernandes, Jose Carlos
    Landeiro, Raquel
    REVISTA PORTUGUESA DE PNEUMOLOGIA, 2009, 15 (04) : 683 - 696
  • [36] Inhibition of Ribonucleotide Reductase Subunit 2 (RRM2) Induces Radiosensitization in Gastroenteropancreatic Neuroendocrine Tumors
    Chow, Z.
    Johnson, J.
    Chauhan, A.
    Izumi, T.
    Cavnar, M.
    Weiss, H.
    Anthony, L.
    Evers, B. M.
    Rychahou, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S160 - S160
  • [37] Adenoviral shRNA vector targeting ribonucleotide reductase M1 (RRM1) has a strong antitumor activity and decrease the drug resistance to GEM in RRM1-overexpressing bladder cells.
    Zhang, Xia
    Liu, Dage
    Taoka, Rikiya
    Sugimoto, Mikio
    Kakehi, Yoshiyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] EXPRESSION AND POSSIBLE ROLE OF RIBONUCLEOTIDE REDUCTASE SUBUNIT M2 (RRM2) IN ENDOMETRIOSIS
    Jeon, Y. E.
    Lee, Y.
    Jung, J. A.
    Seo, S. K.
    Choi, Y. S.
    Cho, S.
    FERTILITY AND STERILITY, 2012, 98 (03) : S219 - S219
  • [39] Excision Repair Cross Complementing 1 (ERCC1) and Ribonucleotide Reductase Regulatory Subunit M1 (RRM1) as Predictors of Survival and Response in Pancreatic Ductal Adenocarcinoma Treated with Gemcitabine-Based Chemotherapy
    Holdbrook, T.
    Danenberg, K. D.
    Satti, S.
    Kline, J.
    Yeo, C. J.
    Brody, J. R.
    McCue, P.
    Witkiewicz, A. K.
    MODERN PATHOLOGY, 2011, 24 : 362A - 362A
  • [40] Excision Repair Cross Complementing 1 (ERCC1) and Ribonucleotide Reductase Regulatory Subunit M1 (RRM1) as Predictors of Survival and Response in Pancreatic Ductal Adenocarcinoma Treated with Gemcitabine-Based Chemotherapy
    Holdbrook, T.
    Danenberg, K. D.
    Satti, S.
    Kline, J.
    Yeo, C. J.
    Brody, J. R.
    McCue, P.
    Witkiewicz, A. K.
    LABORATORY INVESTIGATION, 2011, 91 : 362A - 362A
12345